All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Partner Perspectives: Mesenchymal Stromal Cells Could Serve as Preventive Therapy for Chronic Radiation-Induced Dry Mouth

November 8th 2024

Immune Profile Score Algorithmic Test Is Now Available to Help Inform Checkpoint Inhibitor Use in Cancer

November 7th 2024

The Immune Profile Score algorithmic test is now available for clinical use as a prognostic tool for immune checkpoint inhibitors in solid tumors.

Explore Emerging Breast Cancer Treatment Trends With Kevin Kalinsky, MD, MS

November 7th 2024

Kevin Kalinsky, MD, MS, discusses his top takeaways from the 2024 ASCO Annual Meeting and 2024 ESMO Congress, as well as where he sees the field of breast cancer evolving into the future.

DK210 (EGFR) Induces Immune Response Without Increased CRS or Regulatory T Cells in Solid Tumors

November 7th 2024

DK210 (EGFR) showed evidence of wild-type IL-2 signaling, CRS mitigation, and immune response signaling in patients with solid tumors.

Siglec-15 Represents Potential Therapeutic Target in NSCLC, Other Solid Tumors

November 7th 2024

Siglec-15 was expressed in tumor cells and tumor-associated macrophages in tissue samples from non–small cell lung cancer and other solid tumors.

Radiomic Biomarkers Predict Response in Lung and Liver Uveal Melanoma Metastases

November 7th 2024

Radiomic biomarkers can predict treatment response through assessments of tumor growth in patients with metastatic uveal melanoma treated with roginolisib.

BT7480 Shows Preliminary Activity in Nectin-4+, CD137+ Tumors

November 7th 2024

The Nectin-4/CD137 Bicycle–targeted immune cell agonist BT7480 had antitumor activity in patients with Nectin-4– and CD137-expressing tumors.

Moffitt Study Links Methylmalonic Acid to Weakening of Immune Cells in Lung Cancer

November 7th 2024

A new study has found a surprising link between high levels of methylmalonic acid and the weakening of CD8+ T cells, shedding light on potential pathways through which aging may promote lung cancer progression.

FDA Grants Orphan Drug Designation to MB-108 for Malignant Glioma

November 7th 2024

The FDA has granted orphan drug designation to the herpes simplex virus type 1 oncolytic virus MB-108 for the management of malignant glioma.

Padeliporfin VTP Maintains Robust Responses and is Safe in Low-Grade Upper-Tract Urothelial Cancer

November 7th 2024

Updated interim data show high complete responses and tolerability with padeliporfin VTP in low-grade upper tract urothelial cancer.

42nd Annual CFS Preview for Medical Oncologists: The Show and After Show

November 7th 2024

OncLive co-hosts Kristie L. Kahl and Andrew Svonavec talk to program co-chair Benjamin P. Levy, MD, to highlight what to expect in the latest oncology developments from the 42nd Annual Chemotherapy Foundation Symposium to be held in New York City.

AE Profiles and Dosing Schedules Define the Role of CDK4/6 Inhibitors in HR+ Metastatic Breast Cancer

November 7th 2024

Kari Wisinski, MD, discusses factors that influence her decision between CDK4/6 inhibitors for patients with treatment-naive, HR+ metastatic breast cancer.

Enfortumab Vedotin Plus Pembrolizumab Leads to Shifts in Frontline Metastatic Urothelial Cancer Management

November 7th 2024

Janaki Neela Sharma, MD, discusses the road to FDA approval for enfortumab vedotin plus pembrolizumab in locally advanced or metastatic urothelial cancer.

MAGEA4 Opens the Door for Engineered Cellular Therapies in Solid Tumors

November 7th 2024

Brian A. Van Tine, MD, PhD, and David S. Hong, MD, discuss the MAGEA4 pathway and the FDA approval of afami-cel in synovial sarcoma.

Mirdametinib May Provide Long-Awaited Treatment Alternative for Adults/Children With NF1-PNs

November 6th 2024

Angela Hirbe, MD, PhD, discusses the potential significance of MET inhibitors such as mirdametinib for adult and pediatric patients with NF1-PN.

Zongertinib Research Could Represent Next Wave in HER2-Mutated NSCLC Management

November 6th 2024

Christina S. Baik, MD, MS, discusses the types of HER2 testing that should be performed in NSCLC and the design of the phase 3 Beamion LUNG-2 trial.

NICE Advocates Reimbursement for Avapritinib in Aggressive Systemic Mastocytosis, Other Hematologic Malignancies

November 6th 2024

NICE issued a final guidance recommending reimbursement of avapritinib monotherapy in adult patients with ASM, SM-AHN, or mast cell leukemia.

Julia “Julie” Borrelli Named Chair of the Abramson Cancer Center Director's Leadership Council

November 6th 2024

Julia “Julie” Borrelli has been appointed chair of the Abramson Cancer Center Director's Leadership Council.

MI Cancer Seek Receives FDA Approval as Companion Diagnostic for Targeted Therapy Across Tumor Types

November 6th 2024

MI Cancer Seek has been granted FDA approval as a companion diagnostic for patients with cancer who may benefit from targeted therapy.

FDA Grants Orphan Drug Designation to LBL-034 for Multiple Myeloma

November 6th 2024

The FDA has granted orphan drug designation to LBL-034 for the treatment of patients with multiple myeloma.